Free Trial

Biorestorative Therapies (BRTX) Competitors

Biorestorative Therapies logo
$0.35 0.00 (0.00%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$0.36 +0.01 (+2.13%)
As of 06/12/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BRTX vs. CCM, MRAI, BMGL, ACON, and ADVB

Should you buy Biorestorative Therapies stock or one of its competitors? MarketBeat compares Biorestorative Therapies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biorestorative Therapies include Concord Medical Services (CCM), Marpai (MRAI), Basel Medical Group (BMGL), Aclarion (ACON), and Advanced Biomed (ADVB). These companies are all part of the "healthcare" industry.

How does Biorestorative Therapies compare to Concord Medical Services?

Biorestorative Therapies (NASDAQ:BRTX) and Concord Medical Services (NYSE:CCM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Biorestorative Therapies has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, Concord Medical Services has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market.

Concord Medical Services has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Concord Medical Services' return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Biorestorative Therapies-3,088.27% -508.42% -230.94%
Concord Medical Services N/A N/A N/A

69.4% of Biorestorative Therapies shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by company insiders. Comparatively, 46.5% of Concord Medical Services shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Concord Medical Services had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 3 mentions for Concord Medical Services and 2 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.44 beat Concord Medical Services' score of 0.22 indicating that Biorestorative Therapies is being referred to more favorably in the media.

Company Overall Sentiment
Biorestorative Therapies Neutral
Concord Medical Services Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biorestorative Therapies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Concord Medical Services
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Concord Medical Services has higher revenue and earnings than Biorestorative Therapies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biorestorative Therapies$360K24.95-$14.24M-$1.07N/A
Concord Medical Services$65.85M0.29-$13.27MN/AN/A

Summary

Concord Medical Services beats Biorestorative Therapies on 7 of the 11 factors compared between the two stocks.

How does Biorestorative Therapies compare to Marpai?

Marpai (NASDAQ:MRAI) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Marpai has a net margin of -85.70% compared to Biorestorative Therapies' net margin of -3,088.27%. Marpai's return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Marpai-85.70% N/A -100.23%
Biorestorative Therapies -3,088.27%-508.42%-230.94%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marpai
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Biorestorative Therapies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Biorestorative Therapies had 2 more articles in the media than Marpai. MarketBeat recorded 2 mentions for Biorestorative Therapies and 0 mentions for Marpai. Biorestorative Therapies' average media sentiment score of 0.44 beat Marpai's score of 0.00 indicating that Biorestorative Therapies is being referred to more favorably in the news media.

Company Overall Sentiment
Marpai Neutral
Biorestorative Therapies Neutral

Marpai has a beta of 4.94, meaning that its stock price is 394% more volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

49.8% of Marpai shares are owned by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are owned by institutional investors. 46.1% of Marpai shares are owned by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Biorestorative Therapies has lower revenue, but higher earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marpai$34.87M0.42-$28.75M-$0.87N/A
Biorestorative Therapies$360K24.95-$14.24M-$1.07N/A

Summary

Marpai beats Biorestorative Therapies on 8 of the 14 factors compared between the two stocks.

How does Biorestorative Therapies compare to Basel Medical Group?

Biorestorative Therapies (NASDAQ:BRTX) and Basel Medical Group (NASDAQ:BMGL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

In the previous week, Basel Medical Group had 6 more articles in the media than Biorestorative Therapies. MarketBeat recorded 8 mentions for Basel Medical Group and 2 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.44 beat Basel Medical Group's score of 0.23 indicating that Biorestorative Therapies is being referred to more favorably in the media.

Company Overall Sentiment
Biorestorative Therapies Neutral
Basel Medical Group Neutral

69.4% of Biorestorative Therapies shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Biorestorative Therapies has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Basel Medical Group has higher revenue and earnings than Biorestorative Therapies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biorestorative Therapies$360K24.95-$14.24M-$1.07N/A
Basel Medical Group$11.32M0.98-$9.50MN/AN/A

Basel Medical Group has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Basel Medical Group's return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Biorestorative Therapies-3,088.27% -508.42% -230.94%
Basel Medical Group N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biorestorative Therapies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Basel Medical Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Basel Medical Group beats Biorestorative Therapies on 6 of the 11 factors compared between the two stocks.

How does Biorestorative Therapies compare to Aclarion?

Biorestorative Therapies (NASDAQ:BRTX) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Biorestorative Therapies has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Aclarion has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

In the previous week, Aclarion had 2 more articles in the media than Biorestorative Therapies. MarketBeat recorded 4 mentions for Aclarion and 2 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.44 beat Aclarion's score of 0.31 indicating that Biorestorative Therapies is being referred to more favorably in the media.

Company Overall Sentiment
Biorestorative Therapies Neutral
Aclarion Neutral

Biorestorative Therapies has a net margin of -3,088.27% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -54.41% beat Biorestorative Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Biorestorative Therapies-3,088.27% -508.42% -230.94%
Aclarion -10,320.51%-54.41%-51.71%

Aclarion has lower revenue, but higher earnings than Biorestorative Therapies. Aclarion is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biorestorative Therapies$360K24.95-$14.24M-$1.07N/A
Aclarion$80K95.94-$7.23M-$9.03N/A

Aclarion has a consensus price target of $7.50, suggesting a potential upside of 140.38%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than Biorestorative Therapies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biorestorative Therapies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aclarion
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

69.4% of Biorestorative Therapies shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by company insiders. Comparatively, 0.0% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Aclarion beats Biorestorative Therapies on 9 of the 16 factors compared between the two stocks.

How does Biorestorative Therapies compare to Advanced Biomed?

Advanced Biomed (NASDAQ:ADVB) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

In the previous week, Biorestorative Therapies had 1 more articles in the media than Advanced Biomed. MarketBeat recorded 2 mentions for Biorestorative Therapies and 1 mentions for Advanced Biomed. Advanced Biomed's average media sentiment score of 1.89 beat Biorestorative Therapies' score of 0.44 indicating that Advanced Biomed is being referred to more favorably in the media.

Company Overall Sentiment
Advanced Biomed Very Positive
Biorestorative Therapies Neutral

Advanced Biomed has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Advanced Biomed's return on equity of 87.74% beat Biorestorative Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Advanced BiomedN/A 87.74% 64.49%
Biorestorative Therapies -3,088.27%-508.42%-230.94%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Advanced Biomed
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Biorestorative Therapies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Advanced Biomed has higher earnings, but lower revenue than Biorestorative Therapies. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanced BiomedN/AN/A-$3.26M$4.820.93
Biorestorative Therapies$360K24.95-$14.24M-$1.07N/A

Advanced Biomed has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

69.4% of Biorestorative Therapies shares are owned by institutional investors. 27.0% of Advanced Biomed shares are owned by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Advanced Biomed beats Biorestorative Therapies on 9 of the 12 factors compared between the two stocks.

Get Biorestorative Therapies News Delivered to You Automatically

Sign up to receive the latest news and ratings for BRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BRTX vs. The Competition

MetricBiorestorative TherapiesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$8.98M$3.39B$6.52B$12.05B
Dividend YieldN/A2.25%2.67%5.66%
P/E Ratio-0.3320.0024.0024.42
Price / Sales24.95306.76515.84118.72
Price / CashN/A53.6127.4837.92
Price / Book8.818.3210.606.82
Net Income-$14.24M$23.94M$3.57B$337.56M
7 Day Performance-2.62%1.84%0.59%1.16%
1 Month Performance83.40%-0.04%1.54%3.16%
1 Year Performance-79.02%44.82%25.41%30.60%

Biorestorative Therapies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BRTX
Biorestorative Therapies
0.5576 of 5 stars
$0.35
flat
N/A-79.0%$8.98M$360KN/A7
CCM
Concord Medical Services
0.5092 of 5 stars
$4.63
-1.7%
N/A-32.8%$20.09M$65.85MN/A970
MRAI
Marpai
N/A$0.52
-8.8%
N/A-59.0%$13.30M$34.87MN/A150
BMGL
Basel Medical Group
0.7243 of 5 stars
$0.59
-8.0%
N/A-83.0%$11.03M$8.90MN/A36
ACON
Aclarion
3.6532 of 5 stars
$3.16
-3.1%
$7.50
+137.3%
-58.1%$7.77M$80KN/A7

Related Companies and Tools


This page (NASDAQ:BRTX) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners